Issues Related to Monitoring the Safety of Over-The-Counter (OTC) Medicines

Drug Safety

Volumn 26, Issue 15, 2003, Pages 1065-1074

  Bond, Christine ^a   Hannaford, Philip ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINO ACID DERIVATIVE; ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; ENZYME; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HORMONE; HYDROCORTISONE; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; IMIDAZOLE DERIVATIVE; INDINAVIR; KAVA; LEVONORGESTREL; LOPERAMIDE; MEBEVERINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; ROYAL JELLY; TERFENADINE; TRAMADOL; TRANQUILIZER; UNINDEXED DRUG; VENLAFAXINE; VITAMIN; WARFARIN;

ADVERTIZING; ALLERGIC RHINITIS; BLEEDING; CLINICAL PHARMACY; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG COST; DRUG FATALITY; DRUG LEGISLATION; DRUG MARKETING; DRUG MISUSE; DRUG MONITORING; DRUG SAFETY; ELECTRONICS; EPIDEMIOLOGICAL DATA; FOLLOW UP; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH EDUCATION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IRRITABLE COLON; LICENSING; LIVER TOXICITY; MEDICAL CARE; PATIENT EDUCATION; PHARMACODYNAMICS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SELF MEDICATION; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM; VAGINA CANDIDIASIS;

DRUGS, NON-PRESCRIPTION; HUMANS; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; SAFETY; SELF MEDICATION;

EID: 0346249839     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326150-00001     Document Type: Review

References (41)

1. Boersma E, Mercado N, Poldermans D, et al. Acute myocardial infarction. Lancet 2003; 361: 847-58
2. EEC Directive 2001/83/EEC
3. Potts M, Denny C. Safety implications of transferring the oral contraceptive from prescription only to over the counter status. Drug Saf 1995; 13 (6): 333-7
4. China Concept Consulting: the OTC market - ready for take-off [online]. Available from URL: http://www.chinaconcept.com [Accessed 2002 Oct 3]
5. Effect of herb medicine regulation on industry likely to be minimal [abstract]. Pharm J 2002; 269: 560
6. IMS data global self medication market 1997 [online]. Available from URL: http://www.otc-bulletin.com [Accessed Oct 3]
7. UK to regulate and control all alternative health therapies. Available from URL: http://www.lightnet.co.uk/informer/ health/20001127.htm [Accessed 2002 Oct 3]
8. British Medical Association. Complementary medicine: new approaches to good practice. Oxford: Oxford University Press, 1993: 9-36
9. Barnes J, Abbot N. Experiences with complementary remedies: a survey of community pharmacists [abstract]. Pharm J 1999; 263: R37
10. Bond CM. Prescribing in community pharmacy: barriers and opportunities [PhD thesis] University of Aberdeen, 1995
11. Bissell P, Ward PR, Noyce PR. Consumer preceptions of the risks and benefits of deregulated medicines [abstract]. Pharm J 1999; 263: R28-9
12. Bond CM. Sinclair HK, Taylor RJ, et al. Community pharmacists' attitudes to the deregulation of medicines and to their extended role. Int J Pharm Pract 1993; 2: 26-30
13. Largue G. B Med Sci [dissertation]. University of Aberdeen, 2000
14. Sinclair HK, Bond CM, Hannaford PC. Over the counter ibuprofen: how and why is it used. Int J Pharm Pract 2000; 8: 121-7
15. Layton D, Sinclair HK, Bond CM, et al. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf 2002; 11: 503-13
16. Hannaford PC. Combined oral contraceptive use and venous thromboembolism. Gynecolog Endocrinol 1996; 10 Suppl. 2: 13-8
17. Strom BL. Sample size considerations for pharmacoepidemiologic studies. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989: 27-37
18. Strom BL. Choosing among the available approaches for pharmacoepidemiologic studies. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989: 245-56
19. Baum C, Annello C. The spontaneous reporting system in the United Sates. In: Strom BL, editor. Pharmacoepidemiology. New York: Churchill Livingstone, 1989: 107-18
20. Jarernsiripornkul N, Krska J, Capps PAG, et al. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002; 53: 318-25
21. Egberts TCG, Smulders M, de Koning FHP, et al. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996; 313: 530-1
22. Committee on Safety of Medicines. Aspirin and Reyes syndrome in children up to and including 15 years of age. Current Problems in Pharmacovigilance 2002 Apr; 28: 5
23. Committee on Safety of Medicines and Medicines Control Agency. Ventricular arrhythmias due to terfenadine and astemizole. Current Problems in Pharmacovigilance 1992 Nov; 35: 1
24. Terfenadine switches back to POM. Pharm J 1997; 259: 316
25. POM-to-P shift proposed for budesonide and P-to-POM for carbaryl. Pharm J 1995; 255: 138
26. Kernan WN, Viscoli CM, Brass LM, et al. Phenyl propanolamine and haemorrhagic stroke. N Engl J Med 2000; 348: 1826-32
27. Meckstroth S, Schwartz M, Agrawal N. NSAIDS: safety implications of over the counter availability. Drug Saf 1992; 7 (4): 241-4
28. Singh G. Gastro intestinal complications of prescription and over-the-counter non-steroidal anti inflammatory drugs: a view from the ARMIS database. Am J Ther 2000; 7: 115-21
29. Moore N, Van Ganse E, Le Parc JM, et al. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. Clin Drug Invest 1999; 18 (2): 89-98
30. Rantucci M, Segal H. Over-the-counter medication: outcome and effectiveness of patient counselling. J Soc Admin Pharm 1986; 3 (3): 81-91
31. Sihvo S, Klaukka T, Martikainen J, et al. Frequency of daily over the counter drug use and potentially clinically significant over the counter prescription drug interactions in the Finnish adult population. Eur J Clin Pharmacol 2000; 56: 495-9
32. Perharic L, Shaw D, Colbridge M, et al. Toxicological problems resulting from exposure to traditional remedies and food supplements. Drug Saf 1994; 11 (4): 284-94
33. Palmer ME, Haller C, McKinney PE, et al. Adverse events associated with dietary supplements: an observational study. Lancet 2003; 361: 101-6
34. Breckenridge A. CSM advice on liver toxicity associated with kava-kava and proposed regulatory action by the government Committee on Safety of Medicines CEM/CMO/2002/10
35. Committee on Safety of Medicines. Reminder: St John's wort Interactions. Current Problems in Pharmacovigilance 2000 May; 26: 5
36. Hanlon JT, Fillenbaum GG, Fuby CM, et al. Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging 2001; 18 (2): 123-31
37. Pitkala KH, Strandberg E, Tilvis RS. Is it possible to reduce polypharmacy in the elderly? A randomised controlled trial. Drugs Aging 2001; 18: 143-9
38. Simon HK, Weinkle DA. Over the counter medications. Arch Paediatr Adolesc Med 1997; 151: 654-6
39. The Pharmacy Plan Department of Health 2000, England
40. The Right Medicine. A strategy for pharmaceutical care in Scotland. Scottish Executive 2002
41. Porteous T, Bond C, Hannaford P, et al. Electronic transfer of prescription related information: comparing the views of patients, GPs and pharmacists. Br J Gen Pract 2003; 53: 204-9